Alseres Pharmaceuticals Inc (ALSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2005 | 06-2005 | 03-2005 | 12-2004 | 09-2004 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,971 | 1,211 | 3,765 | 153 | 18 |
| Marketable Securities | 9,438 | 1,450 | 1,199 | 1,490 | 7,611 |
| Other current assets | 437 | 281 | 387 | 0 | 284 |
| TOTAL | $12,845 | $2,943 | $5,351 | $1,788 | $7,912 |
| Non-Current Assets | |||||
| PPE Net | 332 | 312 | 352 | 400 | 446 |
| Other Non-Current Assets | 441 | 377 | 358 | 356 | 384 |
| TOTAL | $772 | $689 | $710 | $757 | $829 |
| Total Assets | $13,617 | $3,631 | $6,061 | $2,545 | $8,741 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,160 | 1,784 | 1,752 | 1,976 | 2,081 |
| Accrued Expenses | 107 | N/A | N/A | N/A | N/A |
| TOTAL | $2,267 | $1,784 | $1,752 | $1,976 | $6,166 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 282 | 0 | 0 | 0 | 0 |
| TOTAL | $282 | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,549 | $1,784 | $1,752 | $1,976 | $6,166 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 3 | 2 | 2 | 2 | 1 |
| Common Shares | 164 | 104 | 104 | 69 | 345 |
| Retained earnings | -113,939 | -110,389 | -107,991 | -105,647 | -103,697 |
| Other shareholders' equity | -11 | 2 | 0 | -5 | -14 |
| TOTAL | $11,069 | $1,847 | $4,308 | $569 | $2,576 |
| Total Liabilities And Equity | $13,617 | $3,631 | $6,060 | $2,545 | $8,741 |